Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

L19TNFα in Patients With Advanced Solid Tumors

ABSTRACT: The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues. Tumor-targeted L19TNFα would result in high and sustained intralesional bioactive TNFα concentrations.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms,Solid Tumors

PROVIDER: 2099056 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Steroid sulfatase is a therapeutic target for advanced prostate cancer

Project description:The conversion of DHEAS into DHEA by steroid sulfatase (STS) may contribute to sustained intracrine androgen synthesis. Here, we determine the contribution of STS to treatment resistance and explore the potential of targeting STS using novel inhibitors to overcome resistance in prostate cancer.

2020-06-26 | GSE153245 | GEO

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Project description:This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug. The purpose of this study is to evaluate the safety, determine the maximum-tolerated dose (MTD) and characterize the pharmacokinetic profile of ALT-801 in previously treated patients with progressive metastatic malignancies. ALT-801, a recombinant fusion protein with a interleukin-2 (IL-2) component, has a targeting mechanism that recognizes tumor cells with a specific tumor marker.

| 2041748 | ecrin-mdr-crc

Effect of endothelial-specific endorepellin expression on gene expression of breast cancer allografts in Tie2CreER;ERKi mice

Project description:To explore the translational implications of endorepellin in breast cancer, we created a double transgenic, inducible Tie2CreER;ERKi mouse line that expresses recombinant endorepellin specifically from the endothelium. We investigated the therapeutic effects of recombinant endorepellin overexpression in an orthotopic, syngeneic breast cancer allograft mouse model. Tamoxifen-induced expression of recombinant endorepellin specifically from the endothelium in Tie2CreER;ERKi mice markedly suppressed breast cancer allograft growth, hyaluronan deposition in the tumor proper and perivascular tissues, and tumor angiogenesis.

2022-11-30 | GSE209743 | GEO

Site-specific N-linked glycosylation of recombinant SARS-CoV-1 and -2 Receptor Binding Domain from GnTI-/- cells

Project description:Fusion proteins of the SARS-CoV-1 and SARS-CoV-2 spike receptor binding domain with a fluorescent protein were created in monomeric and trimeric form as tools for receptor binding studies in cultured cells and animal tissues. Here, site specific N-linked glycosylation in the proteins expressed from GnTI-/- cells is profiled with LC-MS/MS, using electron transfer high-energy collision dissociation

2021-02-02 | PXD021825 | Pride

Automated generation of hiPSC-derived hepatic progeny by cost-efficient compounds

Project description:Human pluripotent stem cell (hPSC)-derived hepatocyte-like cells (HLCs) hold great promise for liver disease modeling, drug discovery, drug toxicity screens, or even regenerative therapies. Yet, several hurdles still need to be overcome, including among others decrease in the cost of goods to generate HLCs and automation of the differentiation process. We here describe that use of an automated liquid handling system results in highly reproducible HLC differentiation from hPSCs. This enabled us to screen 92 chemicals to replace expensive growth factors at each step of the differentiation protocol to reduce the cost of goods of the differentiation protocol by approximately 79%. In addition, we also evaluated several recombinant extracellular matrices (ECM) to replace Matrigel. We demonstrated that differentiation of hPSCs on Laminin-521 using an optimized small molecule combination resulted in HLCs that were transcriptionally identical to HLCs generated using current growth factor combinations. In addition, the HLCs created using the optimized small molecule combination also secreted similar concentrations of albumin and urea, and relatively low concentrations of alfa-fetoprotein (AFP), displayed similar CYP3A4 functionality and a similar drug toxicity susceptibility as HLCs generated with growth factor cocktails. The broad applicability of the new differentiation protocol was demonstrated for four different hPSC lines. This allowed the creation of a scalable, xeno-free, and cost-efficient hPSC-derived HLC culture, suitable for high throughput disease modeling and drug screenings, or even for the creation of HLCs for regenerative therapies.

2024-02-26 | GSE207569 | GEO

Project description:CRISPR/Cas9 targeting of fusion oncogenes

| PRJNA659633 | ENA

A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors

Project description:Interleukin-12 (IL12) is a pro-inflammatory cytokine with potent anti-cancer activity. Attempts to develop recombinant IL12 as a biopharmaceutical have been hampered by severe toxicity, observed already at daily dose of 500 ng/kg. The antibody-based delivery of IL12 significantly increases the therapeutic index of the cytokine but does not completely prevent side effects associated with peak concentrations of the product in blood upon intravenous administration. Here we describe an innovative technology, named “Intra-CORK”, engineered to mask systemic IL12 activity without impacting anti-tumor efficacy. Our strategy relies on the transient inhibition of the intracellular signaling of IL12 by a kinetically-matched pre-administration of Ruxolitinib, a commercially available JAK2 inhibitor. When treating tumor-bearing mice with the L19-IL12 fusion protein, targeting alternatively-spliced fibronectin, we achieved a long residence time of the cytokine within the tumor with rapid clearance from circulation. The short half-life of Ruxolitinib substantially increased the tolerability profile of L19-IL12 while preserving anti-tumor activity. Our technology relies on judiciously-chosen inhibitors matching circulatory half-lives of biopharmaceuticals and may be broadly applied to other antibody-cytokine fusion products in clinical trials

2024-01-25 | PXD047339 | Pride

Targeting DNMTs to overcome enzalutamide resistance in prostate cancer

Project description:Targeting DNMTs to overcome enzalutamide resistance in prostate cancer

| PRJNA763500 | ENA

Alu repeats blocking and CEBPA overexpression in BLaER1 cells, CEBPA ChIP-Seq

Project description:Weaker CEBPA binding in the human than in the mouse genome is a general trait of the human genome across multiple biological conditions. Alu repeats carry strong CEBPA binding motifs, which compete with regulatory regions for CEBPA binding. To directly test this hypothesis, we attempted to overcome Alu competition by using, first, a CRISPR-dCas9 system in BLaER1 cells (Rapino et al. 2013). By promoting the recruitment of the inactive Cas9 to Alu regions with specific gRNAs targeting Alu repeats containing strong CEBPA motifs we protected them, hampering CEBPA binding to these regions. We tested the effect of two different paired gRNA constructs in two replicates and one control paired gRNA in two replicates. Second, we also further overexpressed CEBPA in human BLaER1 cells to overcome Alu competition. We tested two doses of CEBPA overexpression in two replicates and one control experiment in two replicates.

2023-05-01 | E-MTAB-12597 | biostudies-arrayexpress

Mus musculus

Project description:Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy

| PRJNA313284 | ENA